<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990753</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS1901</org_study_id>
    <nct_id>NCT03990753</nct_id>
  </id_info>
  <brief_title>Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)</brief_title>
  <official_title>Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901): A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital, Medical School, Southeast University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Second Provincial General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xingtai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Hospital of Zhenjiang Affiliated Jiangsu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University Lishui Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Second Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The sixth people's hospital of Shenyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi’an Gaoxin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Variceal hemorrhage is a lethal complication in patients with cirrhosis and portal
      hypertension. Identification of varices needing treatment in compensated cirrhosis is,
      therefore, of great therapeutic and prognostic importance. The gold standard for diagnosing
      gastroesophageal varices and evaluating the risk of variceal hemorrhage is
      esophagogastroduodenoscopy. According to the Baveno VI consensus, for those with high-risk
      varices (HRV), either non-selective beta blockers or endoscopic band ligation is recommended
      for the prevention of the first variceal bleeding. However, the invasiveness and
      uncomfortableness during the esophagogastroduodenoscopy procedure has hindered its use in
      clinical practice, especially in patients with compensated cirrhosis. Sufficient accurate
      non-invasive tools for detection of HRV are warranted to safely avoid the use of
      esophagogastroduodenoscopy.

      Advanced technologies including next-generation sequencing and MALDI-TOF mass spectrometry
      have the potential to be applied in this field. The latter is a widespread adopted tool in
      clinical microbiology for rapid, accurate and cost-effective identification of cultured
      bacteria and fungi. Recently, microbiome and peptidome have been proved their roles in the
      end-stage liver disease (e.g. cirrhosis, hepatocellular carcinoma), which may exhibit
      predictive capacity of HRV. In the present study, the investigators aim to conduct a
      prospective, multicenter diagnostic trial in 12 sites in China, 1 site in Turkey and 1 site
      in Thailand to evaluate the diagnostic performance of the microbiome/peptidome-based model
      for HRV detection in compensated cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal hemorrhage is a lethal complication in patients with cirrhosis and portal
      hypertension. Identification of varices needing treatment in compensated cirrhosis is,
      therefore, of great therapeutic and prognostic importance. The gold standard for diagnosing
      gastroesophageal varices and evaluating the risk of variceal hemorrhage is
      esophagogastroduodenoscopy. According to the Baveno VI consensus, for those with high-risk
      varices (HRV), either non-selective beta blockers or endoscopic band ligation is recommended
      for the prevention of the first variceal bleeding. However, the invasiveness and
      uncomfortableness during the esophagogastroduodenoscopy procedure has hindered its use in
      clinical practice, especially in patients with compensated cirrhosis. Sufficient accurate
      non-invasive tools for detection of HRV are warranted to safely avoid the use of
      esophagogastroduodenoscopy.

      Advanced technologies including next-generation sequencing and MALDI-TOF mass spectrometry
      have the potential to be applied in this field. The latter is a widespread adopted tool in
      clinical microbiology for rapid, accurate and cost-effective identification of cultured
      bacteria and fungi. Recently, microbiome and peptidome have been proved their roles in the
      end-stage liver disease (e.g. cirrhosis, hepatocellular carcinoma), which may exhibit
      predictive capacity of HRV. In the present study, the investigators aim to conduct a
      prospective, multicenter diagnostic trial in 12 sites (The First Hospital of Lanzhou
      University; Zhujiang Hospital of Southern Medical University; Nanfang Hospital of Southern
      Medical University; Xingtai People's Hospital; Zhongda Hospital, Medical School, Southeast
      University; The Third People's Hospital affiliated to Jiangsu University; Guangdong Second
      Provincial General Hospital; Tianjin Infectious Disease Hospital; Lishui Municipal Central
      Hospital; The Second Hospital of Anhui Medical University; Xi'an Gaoxin Hospital; The Sixth
      People's Hospital of Shenyang) in China, 1 site (Ankara University School of Medicine) in
      Turkey and 1 site (King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn
      University) in Thailand to evaluate the diagnostic performance of the
      microbiome/peptidome-based model for HRV detection in compensated cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">June 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of microbiome/peptidome-based model for high-risk varices</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic performance of microbiome/peptidome-based model to determine the presence or absence of high-risk varices when compared with esophagogastroduodenoscopy as the reference standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of microbiome/peptidome-based model for decompensation or death</measure>
    <time_frame>3 years</time_frame>
    <description>Diagnostic performance of microbiome/peptidome-based model to determine the presence or absence of decompensation (defined as development of ascites, bleeding, or overt encephalopathy) or death within 3-year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of microbiome/peptidome-based model for hepatic venous pressure gradient</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic performance of microbiome/peptidome-based model to determine the level of hepatic venous pressure gradient</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Compensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Overall eligible participants</arm_group_label>
    <description>Eligible participants will receive standard esophagogastroduodenoscopy and microbiome/peptidome examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>esophagogastroduodenoscopy</intervention_name>
    <description>standard esophagogastroduodenoscopy</description>
    <arm_group_label>Overall eligible participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with compensated cirrhosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75 years;

          -  confirmed compensated cirrhosis based on liver biopsy or clinical findings;

          -  without decompensated events (e.g. ascites, bleeding, or overt encephalopathy);

          -  scheduled to undergo esophagogastroduodenoscopy;

          -  estimated survival time&gt; 24 months, and model for end-stage liver disease (MELD)
             score&lt; 19, and without liver transplant;

          -  with written informed consent.

        Exclusion Criteria:

          -  contradictions for esophagogastroduodenoscopy;

          -  use of antibiotics, prebiotics, probiotics and proton pump inhibitors within 3 months
             upon recruitment.

          -  pregnancy or unknown pregnancy status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongwei Zhou, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Medical University, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolong Qi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, MD</last_name>
    <phone>+8618588602600</phone>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiangpeng Hu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jun Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiangpeng Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Mao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaorong Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liting Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Second Provincial General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Xu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ming Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaofeng Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jinlin Hou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jinlin Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Mao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hua Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingge Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Qingge Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jitao Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital, Medical School, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruihua Shi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruihua Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Zhenjiang Affiliated Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youwen Tan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Youwen Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiying Song, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yiying Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an Gaoxin Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Song, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ying Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bojiang Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jia Li, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jia Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ping Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang University Lishui Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiansong Ji, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jiansong Ji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhongwei Zhao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital affiliated to Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sombat Treeprasertsuk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sombat Treeprasertsuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Necati Örmeci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Necati Örmeci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <reference>
    <citation>He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, Chen MX, Chen ZH, Ji GY, Zheng ZD, Mujagond P, Chen XJ, Rong ZH, Chen P, Lyu LY, Wang X, Wu CB, Yu N, Xu YJ, Yin J, Raes J, Knight R, Ma WJ, Zhou HW. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018 Oct;24(10):1532-1535. doi: 10.1038/s41591-018-0164-x. Epub 2018 Aug 27. Erratum in: Nat Med. 2018 Sep 24;:.</citation>
    <PMID>30150716</PMID>
  </reference>
  <reference>
    <citation>Qi X, Li Z, Huang J, Zhu Y, Liu H, Zhou F, Liu C, Xiao C, Dong J, Zhao Y, Xu M, Xing S, Xu W, Yang C. Virtual portal pressure gradient from anatomic CT angiography. Gut. 2015 Jun;64(6):1004-5. doi: 10.1136/gutjnl-2014-308543. Epub 2014 Nov 14.</citation>
    <PMID>25398771</PMID>
  </reference>
  <reference>
    <citation>Qi X, An W, Liu F, Qi R, Wang L, Liu Y, Liu C, Xiang Y, Hui J, Liu Z, Qi X, Liu C, Peng B, Ding H, Yang Y, He X, Hou J, Tian J, Li Z. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Radiology. 2019 Feb;290(2):370-377. doi: 10.1148/radiol.2018180425. Epub 2018 Nov 20.</citation>
    <PMID>30457484</PMID>
  </reference>
  <reference>
    <citation>Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine. 2018 Oct;36:151-158. doi: 10.1016/j.ebiom.2018.09.023. Epub 2018 Sep 27.</citation>
    <PMID>30268833</PMID>
  </reference>
  <reference>
    <citation>Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014 Dec;60(6):2099-108. doi: 10.1002/hep.27406. Epub 2014 Oct 29. Review.</citation>
    <PMID>25164003</PMID>
  </reference>
  <reference>
    <citation>García-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, Schoenenberger A, Manichanh C, Genescà J, Martell M, Augustin S. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 2018 Apr;67(4):1485-1498. doi: 10.1002/hep.29646. Epub 2018 Feb 19.</citation>
    <PMID>29113028</PMID>
  </reference>
  <reference>
    <citation>Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018 Jul;24(7):1070-1080. doi: 10.1038/s41591-018-0061-3. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Aug 9;:.</citation>
    <PMID>29942096</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. Erratum in: Hepatology. 2017 Jul;66(1):304.</citation>
    <PMID>27786365</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 16, 2019</study_first_submitted>
  <study_first_submitted_qc>June 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 16, 2019</last_update_submitted>
  <last_update_submitted_qc>June 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Microbiome/Peptidome</keyword>
  <keyword>High-risk Gastroesophageal Varices</keyword>
  <keyword>Compensated Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

